0001567619-18-003657.txt : 20181003 0001567619-18-003657.hdr.sgml : 20181003 20181003170502 ACCESSION NUMBER: 0001567619-18-003657 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181001 FILED AS OF DATE: 20181003 DATE AS OF CHANGE: 20181003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kunkel Lori Anne CENTRAL INDEX KEY: 0001536368 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181105820 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS, INC. STREET 2: 995 EAST ARQUES AVENUE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-10-01 0 0001581720 Loxo Oncology, Inc. LOXO 0001536368 Kunkel Lori Anne C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 1 0 0 0 Common Stock 2018-10-01 4 M 0 5000 3.648 A 5000 D Common Stock 2018-10-01 4 S 0 4500 170.1958 D 500 D Common Stock 2018-10-01 4 S 0 500 171.8960 D 0 D Director Stock Option (Right to Buy) 3.648 2018-10-01 4 M 0 5000 0 D 2024-06-18 Common Stock 5000 22344 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.00 to $170.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.38 to $172.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested and is immediately exercisable. /s/Jennifer Burstein, by power of attorney 2018-10-03